Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HBV MVA-HBV vaccine component
- Development stage
- Discontinued
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
HBV MVA-HBV vaccine component is an investigational modified vaccinia virus Ankara (MVA)-based viral vector vaccine component developed by GSK for the treatment of chronic hepatitis B virus (HBV) infection. It is designed as part of a heterologous prime-boost immunotherapy regimen (GSK3528869A) that also includes a chimpanzee adenovirus vector (ChAd155-hIi-HBV) and adjuvanted recombinant HBV proteins (HBc-HBs/AS01B-4). The MVA-HBV vector encodes two key HBV antigens: the truncated hepatitis B core antigen (HBcAg) and the full-length small hepatitis B surface antigen (HBsAg). Administered via intramuscular injection, the vaccine aims to stimulate robust HBV-specific CD4+ and CD8+ T-cell immune responses to overcome immune tolerance in chronic carriers. In clinical trials, this immunotherapy regimen was evaluated sequentially following treatment with the antisense oligonucleotide bepirovirsen in patients on nucleos(t)ide analogue therapy. However, in late 2024, GSK terminated the Phase II development of the GSK3528869A regimen due to it failing to meet its primary efficacy endpoint.
- Other names
- Modified Vaccinia Ankara-Hepatitis B Virus vaccine componentMVA-HBV vaccine component
02
Targets
HBsAg (Hepatitis B surface antigen)HBc (Hepatitis B virus core protein)
Beyond the preview
Go deeper on HBV MVA-HBV vaccine component.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HBV MVA-HBV vaccine component.